Form 4: Orchestra BioMed Holdings Executive Receives Stock Award

Darren Sherman, President and COO of Orchestra BioMed Holdings, was granted 115,708 restricted stock units (RSUs) on April 4, 2025, vesting over three years.

Summary

• Darren Sherman, President and Chief Operating Officer of Orchestra BioMed Holdings, received an award of 115,708 restricted stock units (RSUs) on April 4, 2025.
• Each RSU represents the right to receive one share of Common Stock.
• The RSUs vest over a three-year period: 33.33% vest 24 months after the issue date (April 4, 2025), 33.33% vest 30 months after, and 33.34% vest 36 months after, contingent upon continuous service.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders.

Positives

• The grant of RSUs aligns the executive's interests with those of the shareholders, incentivizing long-term performance and commitment to the company.

Risks

• The vesting of the RSUs is contingent upon the Reporting Person's continuous service, so if the Reporting Person leaves the company before the vesting dates, they will forfeit the unvested RSUs.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This type of stock award is a common practice in the biotech industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock awards are a standard component of executive compensation packages in the biotechnology industry.
• Companies like Medtronic and Boston Scientific also use stock awards to align executive incentives with shareholder value.
• The vesting schedule of three years is also typical for RSU grants in this sector.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it incentivizes the executive to drive long-term value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

RSU, restricted stock units, Orchestra BioMed Holdings, Darren Sherman, executive compensation, stock award, OBIO, beneficial ownership